CASP3 and lung carcinoma: In our previous study, by pharmacological exploration, we have found that tumor growth can be inhibited by cell cycle inhibition and antiangiogenesis with the VEGFA epidermal growth factor receptor CASP3 AKT1 CCND1 associated with the prognosis of lung cancer patients [14].